Arcutis Biotherapeutics (ARQT) News Today $14.30 -0.43 (-2.92%) Closing price 04:00 PM EasternExtended Trading$14.29 -0.01 (-0.07%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Franklin Resources Inc. Sells 941,099 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Franklin Resources Inc. trimmed its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 22.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,309,319 shares of thApril 7 at 4:20 AM | marketbeat.comKLP Kapitalforvaltning AS Buys Shares of 24,200 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)KLP Kapitalforvaltning AS acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 24,200 shares of the company's stock, valued atApril 7 at 3:18 AM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Given "Buy" Rating at GuggenheimGuggenheim restated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday.April 5 at 10:48 AM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $20.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday.April 5 at 8:05 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)HC Wainwright reissued a "buy" rating and issued a $19.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday.April 5 at 8:05 AM | marketbeat.comGuggenheim Reiterates Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)April 5 at 1:17 AM | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Earns Buy Rating from HC WainwrightApril 5 at 1:17 AM | americanbankingnews.comArcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade)April 4 at 11:10 PM | seekingalpha.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4 at 4:00 PM | globenewswire.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 12.5% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Trading 12.5% Higher - Here's WhyApril 4 at 2:55 PM | marketbeat.comBrokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.80April 4 at 1:12 AM | americanbankingnews.comArcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent LawsuitApril 3, 2025 | finanznachrichten.deArcutis strategic valued enhanced by patent win, says H.C. WainwrightApril 3, 2025 | markets.businessinsider.com3ARQT : Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst ReviewsApril 3, 2025 | benzinga.comArcutis stock rises following litigation stayApril 3, 2025 | uk.investing.comArcutis Biotherapeutics, Padagis agree to stay patent lawsuitApril 3, 2025 | markets.businessinsider.comWhy Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?April 3, 2025 | msn.comFinalist: Scott BurrowsApril 2, 2025 | latimes.comArcutis and Padagis to pause patent lawsuit over ZoryveApril 2, 2025 | msn.comArcutis and Padagis Agree to Stay Patent LawsuitApril 2, 2025 | globenewswire.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from AnalystsArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buApril 2, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 15,110,000 shares, a decrease of 23.6% from the February 28th total of 19,770,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is currently 6.4 days. Approximately 14.3% of the company's shares are sold short.April 1, 2025 | marketbeat.comPrudential Financial Inc. Has $8.25 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Prudential Financial Inc. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 3.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 592,565 shares of the company's stock after purchasing anMarch 31, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Lifted by American Century Companies Inc.American Century Companies Inc. grew its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,631,226 shares of the company's stock after purchasing an additionMarch 31, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Todd Franklin Watanabe Sells 1,500 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Franklin Watanabe sold 1,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $17.52, for a total value of $26,280.00. Following the sale, the insider now owns 927,414 shares of the company's stock, valued at $16,248,293.28. The trade was a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 27, 2025 | marketbeat.comArcutis to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 27, 2025 | globenewswire.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $26,280.00 in StockMarch 27, 2025 | insidertrades.comArcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week High - Should You Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 52-Week High - Here's WhyMarch 26, 2025 | marketbeat.comSimplify Asset Management Inc. Invests $10.34 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Simplify Asset Management Inc. purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 742,299 shares of the company's stock, vMarch 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $12.24 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Charles Schwab Investment Management Inc. increased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 878,804 shMarch 22, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $21,132.00 in StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Franklin Watanabe sold 1,200 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.61, for a total value of $21,132.00. Following the completion of the sale, the insider now directly owns 928,914 shares in the company, valued at $16,358,175.54. This represents a 0.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 21, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Todd Franklin Watanabe Sells 1,200 SharesMarch 21, 2025 | insidertrades.comPrivium Fund Management B.V. Buys New Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Privium Fund Management B.V. purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 325,709 shares of the company's stMarch 20, 2025 | marketbeat.comTejara Capital Ltd Lowers Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Tejara Capital Ltd lowered its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 886,838 shares of the company's stock afMarch 19, 2025 | marketbeat.comAlphaQuest LLC Sells 35,696 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)AlphaQuest LLC decreased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 83.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,142 shares of the company's stock after selling 35,March 19, 2025 | marketbeat.comPatrick Burnett Sells 12,242 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 12,242 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $15.04, for a total transaction of $184,119.68. Following the sale, the insider now directly owns 121,936 shares in the company, valued at $1,833,917.44. This trade represents a 9.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.March 18, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading 13.1% Higher - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 13.1% - Time to Buy?March 18, 2025 | marketbeat.comArcutis Biotherapeutics shares jumpMarch 18, 2025 | msn.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 12,242 Shares of StockMarch 18, 2025 | insidertrades.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year High - Should You Buy?March 18, 2025 | marketbeat.comErste Asset Management GmbH Has $1.05 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Erste Asset Management GmbH increased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 558.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,100 shares of the compMarch 16, 2025 | marketbeat.comArcutis Biotherapeutics: Topical Derm Player Continues To ExecuteMarch 12, 2025 | seekingalpha.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% After Analyst UpgradeArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 7.1% After Analyst UpgradeMarch 12, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial GroupJefferies Financial Group raised their target price on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Tuesday.March 12, 2025 | marketbeat.comArcutis Biotherapeutics price target raised to $19 from $16 at JefferiesMarch 11, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Cuts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Essex Investment Management Co. LLC cut its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 12.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,823 shares of the company's sMarch 10, 2025 | marketbeat.com151,293 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Bought by Jackson Creek Investment Advisors LLCJackson Creek Investment Advisors LLC acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 151,293 shares of the company's stock, valuMarch 8, 2025 | marketbeat.comArcutis Biotherapeutics announces new data from two posters at 2025 AADMarch 7, 2025 | markets.businessinsider.comArcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology MeetingMarch 7, 2025 | globenewswire.comCandriam S.C.A. Decreases Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Candriam S.C.A. lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,042,144 shares of the company's stockMarch 7, 2025 | marketbeat.com Remove Ads Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.570.64▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼256▲ARQT Articles Average Week Remove Ads Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News Today LNTH News Today BBIO News Today RVMD News Today LEGN News Today TGTX News Today SRPT News Today AXSM News Today BPMC News Today TLX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
